Is COVID-19 severity associated with reduction in T lymphocytes in anti-CD20-treated people with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder?

TY - JOUR

T1 - Is COVID-19 severity associated with reduction in T lymphocytes in anti-CD20-treated people with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder?

AU - Hoepner, Robert

AU - Kamm, Christian P.

AU - Friedli, Christoph

AU - Salmen, Anke

AU - Chan, Andrew

N1 - Funding Information: Dr Hoepner received speaker/advisor honorary from Merck, Novartis, Roche, Biogen, Alexion, Sanofi, Janssen, Bristol‐Myers Squibb, and Almirall. He received research support within the last 5 years from Roche, Merck, Sanofi, Biogen, Chiesi, and Bristol‐Myers Squibb. He also received research grants from the Swiss MS Society. He also serves as associated editor for Journal of Central Nervous System disease. All are not related to that work. Dr Kamm has received honoraria for lectures and research support from Biogen, Novartis, Almirall, Teva, Merck, Sanofi Genzyme, Roche, Eli Lilly, Janssen, Celgene, and the Swiss MS Society (SMSG). Friedli C received speaker honoraria and/or travel compensation for activities with Biogen, Sanofi Genzyme, Novartis, and Merck and research support from Chiesi, not related to this work. Dr Salmen received speaker honoraria and/or travel compensation for activities with Bristol‐Myers Squibb, Novartis, Roche, and research support by Baasch Medicus Foundation and the Swiss MS Society. She serves on the Editorial Board of Frontiers in Neurology—Multiple Sclerosis and Neuroimmunology. All are not related to this work. Dr Chan has received speakers’/board honoraria from Actelion (Janssen/J&J), Almirall, Bayer, Biogen, Celgene (BMS), Genzyme, Merck KGaA (Darmstadt, Germany), Novartis, Roche, and Teva, all for hospital research funds. He received research support from Biogen, Genzyme, and UCB, the European Union, and the Swiss National Foundation. He serves as associate editor of the European Journal of Neurology, on the editorial board for Clinical and Translational Neuroscience and as topic editor for the Journal of International Medical Research.

PY - 2022/6

Y1 - 2022/6

UR - http://www.scopus.com/inward/record.url?scp=85128171422&partnerID=8YFLogxK

U2 - 10.1111/cns.13841

DO - 10.1111/cns.13841

M3 - Letter

C2 - 35411701

AN - SCOPUS:85128171422

SN - 1755-5930

VL - 28

SP - 971

EP - 973

JO - CNS Neuroscience and Therapeutics

JF - CNS Neuroscience and Therapeutics

IS - 6

ER -